Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)

Table 2 Risk of Mycobacterium tuberculosis infection associated with the use of tumor necrosis factor-alpha inhibitors in patients with Crohn’s disease

	n	Risk estimate	95%CI	P value
Risk difference odds ratio	23	0.028	(0.0011, 0.055)	0.042
Including Double-Zero Studies	23	4.85	(1.02, 22.99)	0.047
Excluding Double-Zero Studies	5	5.85	(1.13, 30.38)	0.036

n: Number of individual clinical studies pooled together.